Orforglipron: Trials and FDA Status
Orforglipron is a oral small-molecule glp-1. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- FDA approved as Foundayo (1 Apr 2026)
- Phase
- Approved
- Sponsor
- Eli Lilly
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT05051579, NCT05048719, NCT05869903, NCT05872620, NCT05971940
Reported results
- 2025ATTAIN-1 phase 3 (NEJM 2025): weight change at 72 weeks vs placebo“The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- Lilly reports the submission for orforglipron for type 2 diabetes in the U.S.
- Lilly reports U.S. FDA approval of Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problems
- Orforglipron approved as FoundayoApproval
- Lilly reports submissions for orforglipron for obesity in the U.S. and Japan, and for obesity and type 2 diabetes in the EU
- Published in Lancet (London, England) (2026): Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
- NCT05872620 (ATTAIN-2; Phase 3): primary completion
- NCT05869903 (ATTAIN-1; Phase 3): primary completion
- NCT05971940 (ACHIEVE-1; Phase 3): primary completion
- Published in The New England journal of medicine (2025): Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- NCT05971940 (ACHIEVE-1; Phase 3): study start
- NCT05971940 (ACHIEVE-1; Phase 3): first posted on ClinicalTrials.gov
- NCT05869903 (ATTAIN-1; Phase 3): study start
- NCT05872620 (ATTAIN-2; Phase 3): study start
- NCT05872620 (ATTAIN-2; Phase 3): first posted on ClinicalTrials.gov
- NCT05869903 (ATTAIN-1; Phase 3): first posted on ClinicalTrials.gov
- Published in The New England journal of medicine (2023): Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- NCT05048719 (A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus; Phase 2): primary completion
- NCT05051579 (A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities; Phase 2): primary completion
- NCT05051579 (A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities; Phase 2): study start
- NCT05051579 (A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities; Phase 2): first posted on ClinicalTrials.gov
- NCT05048719 (A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus; Phase 2): first posted on ClinicalTrials.gov
- NCT05048719 (A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus; Phase 2): study start
What the orforglipron registry entries specify
The ATTAIN-1 registry record (NCT05869903) gives its official title as a phase 3, randomised, double-blind study of once-daily oral orforglipron against placebo in adults with obesity or overweight.[4]
ATTAIN-1 enrolled 3127 participants (actual enrolment).[4]
ATTAIN-1 is listed as active, not recruiting, with a start date of 2023-06-05 and an actual primary completion date of 2025-07-25.[4]
ATTAIN-2, the type 2 diabetes trial, enrolled 1613 participants (actual enrolment).[5]
ATTAIN-2 is listed as completed, with a start date of 2023-06-05 and an actual primary completion date of 2025-08-08.[5]
In the phase 2 obesity study (NCT05051579), the 24 mg arm escalated through 3, 6, 8, 12 and then 24 mg orally once daily.[2]
Primary endpoints and trial length
The primary outcome in ATTAIN-1 (NCT05869903) is percent change from baseline in body weight, measured over the primary treatment period.[4]
The primary outcome in ATTAIN-2 (NCT05872620) is percent change from baseline in body weight.[5]
From start to primary completion is 112 weeks for ATTAIN-1 and 114 weeks for ATTAIN-2.
Calculated from NCT05869903 start 2023-06-05, primary completion 2025-07-25, type ACTUAL; NCT05872620 start 2023-06-05, primary completion 2025-08-08, type ACTUAL. Formula: weeks = round((primary completion date - start date) / 7 days)
Published results so far
In the published ATTAIN-1 results, mean body weight changed by -7.5% on 6 mg, -8.4% on 12 mg and -11.2% on 36 mg of orforglipron at week 72, against -2.1% on placebo.[9]
Adverse events led to discontinuation in 5.3 to 10.3% of ATTAIN-1 patients on orforglipron and 2.7% on placebo.[9]
In ATTAIN-2, discontinuation for adverse events, mainly gastrointestinal, was 6.1-9.9% on orforglipron and 4.1% on placebo.[10]
Orforglipron (Foundayo) FDA approval: 1 April 2026
FDA's press release announcing Foundayo (orforglipron) is dated April 01, 2026.[14]
The Foundayo labeling carries a boxed warning for thyroid C-cell tumors.[14]
Conditions listed in the orforglipron trial records
The ATTAIN-1 record lists its conditions as obesity, overweight, and overweight or obesity.[4]
The ATTAIN-2 record lists obesity, overweight and type 2 diabetes as its conditions.[5]
A separate phase 3 record (NCT05971940), in people with inadequate glycemic control on diet and exercise alone, lists type 2 diabetes alone.[6]
The phase 2 obesity record lists obesity and overweight and obesity as its conditions.[2]
Common questions
Is orforglipron FDA approved?
Yes. FDA approved it as Foundayo for adults with obesity, or with overweight and at least one weight-related condition, alongside diet and physical activity.[14]
Sources
- 1FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions (1 Apr 2026)Eli Lilly and Company (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 2A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities (NCT05051579)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 3A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus (NCT05048719)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 4ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 5ATTAIN-2: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (NCT05872620)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 6ACHIEVE-1: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (NCT05971940)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 7Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
- 8Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
- 9Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 10Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 11Lilly reports submissions for orforglipron for obesity in the U.S. and Japan, and for obesity and type 2 diabetes in the EUEli Lilly (press release) · 2026sec.govAccessed 2 Oct 2026
- 12Lilly reports U.S. FDA approval of Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problemsEli Lilly (press release) · 2026sec.govAccessed 2 Oct 2026
- 13Lilly reports the submission for orforglipron for type 2 diabetes in the U.S.Eli Lilly (press release) · 2026sec.govAccessed 2 Oct 2026
- 14Official web pageOfficial web page · web page
Found an error? Report a correction.